Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical lipidology 2019-05, Vol.13 (3), p.374-392 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 392 |
|---|---|
| container_issue | 3 |
| container_start_page | 374 |
| container_title | Journal of clinical lipidology |
| container_volume | 13 |
| creator | Wilson, Don P. Jacobson, Terry A. Jones, Peter H. Koschinsky, Marlys L. McNeal, Catherine J. Nordestgaard, Børge G. Orringer, Carl E. |
| description | Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.
•Causal association between high lipoprotein(a) [Lp(a)] and atherosclerotic cardiovascular disease–related events and mortality.•Laboratory methods and population-based considerations for Lp(a) cut points.•When to measure Lp(a) in adults and youth.•Treatment implications in primary and secondary prevention. |
| doi_str_mv | 10.1016/j.jacl.2019.04.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2233859337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1933287419300868</els_id><sourcerecordid>2233859337</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-876f6eef3e5491729998560c32948f4e94a762c423f57c36ff1ec6f78a4a46e23</originalsourceid><addsrcrecordid>eNp9kUtvEzEUhS0Eog_4AyyQl2Uxg19jjxGbqIKCFMGGri3XuVZumBkH2yniF_C3cZrCkpUf-u65OucQ8oqznjOu3-76nQ9TLxi3PVM94-wJOeej0Z0yo33a7lbKToxGnZGLUnaMDYNhw3NyJjlXRmh7Tn7fFqAp0jXu0z6nCrhc-TcUFxomXDD4ie6zDxUDvKMreodp9vk7ZPpzm9pkxRno1hca0gx9A0pAWCpGDLRUX2FuLxpzmmndAv3iK6alabZ1uKGrUlLAh78X5Fn0U4GXj-cluf344dv1p2799ebz9WrdBSVE7Zq5qAGihEFZboS1dhw0C1JYNUYFVnmjRWNlHEyQOkYOQUczeuWVBiEvydVJt5n9cYBS3YwlwDT5BdKhOCGkHIeWm2moOKEhp1IyRLfP2Nz_cpy5YwFu544FuGMBjinXCmhDrx_1D3czbP6N_E28Ae9PADSX9wjZPUQWYIMZQnWbhP_T_wOYaZc4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2233859337</pqid></control><display><type>article</type><title>Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wilson, Don P. ; Jacobson, Terry A. ; Jones, Peter H. ; Koschinsky, Marlys L. ; McNeal, Catherine J. ; Nordestgaard, Børge G. ; Orringer, Carl E.</creator><creatorcontrib>Wilson, Don P. ; Jacobson, Terry A. ; Jones, Peter H. ; Koschinsky, Marlys L. ; McNeal, Catherine J. ; Nordestgaard, Børge G. ; Orringer, Carl E.</creatorcontrib><description>Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.
•Causal association between high lipoprotein(a) [Lp(a)] and atherosclerotic cardiovascular disease–related events and mortality.•Laboratory methods and population-based considerations for Lp(a) cut points.•When to measure Lp(a) in adults and youth.•Treatment implications in primary and secondary prevention.</description><identifier>ISSN: 1933-2874</identifier><identifier>EISSN: 1876-4789</identifier><identifier>DOI: 10.1016/j.jacl.2019.04.010</identifier><identifier>PMID: 31147269</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Atherosclerotic cardiovascular disease ; Biomarker ; Biomarkers - blood ; Blood Chemical Analysis ; Calcific valvular aortic disease ; Cardiovascular risk ; Coronary heart disease ; Cut points ; Humans ; Hypolipidemic Agents - pharmacology ; Lifestyle ; Lipoprotein (a) ; Lipoprotein(a) - blood ; Lp(a) ; Myocardial infarction ; Practice Guidelines as Topic ; Primary prevention ; Scientific statement ; Secondary prevention ; Societies, Scientific ; Stroke ; Treatment</subject><ispartof>Journal of clinical lipidology, 2019-05, Vol.13 (3), p.374-392</ispartof><rights>2019 National Lipid Association</rights><rights>Copyright © 2019 National Lipid Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-876f6eef3e5491729998560c32948f4e94a762c423f57c36ff1ec6f78a4a46e23</citedby><cites>FETCH-LOGICAL-c422t-876f6eef3e5491729998560c32948f4e94a762c423f57c36ff1ec6f78a4a46e23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jacl.2019.04.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31147269$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilson, Don P.</creatorcontrib><creatorcontrib>Jacobson, Terry A.</creatorcontrib><creatorcontrib>Jones, Peter H.</creatorcontrib><creatorcontrib>Koschinsky, Marlys L.</creatorcontrib><creatorcontrib>McNeal, Catherine J.</creatorcontrib><creatorcontrib>Nordestgaard, Børge G.</creatorcontrib><creatorcontrib>Orringer, Carl E.</creatorcontrib><title>Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association</title><title>Journal of clinical lipidology</title><addtitle>J Clin Lipidol</addtitle><description>Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.
•Causal association between high lipoprotein(a) [Lp(a)] and atherosclerotic cardiovascular disease–related events and mortality.•Laboratory methods and population-based considerations for Lp(a) cut points.•When to measure Lp(a) in adults and youth.•Treatment implications in primary and secondary prevention.</description><subject>Atherosclerotic cardiovascular disease</subject><subject>Biomarker</subject><subject>Biomarkers - blood</subject><subject>Blood Chemical Analysis</subject><subject>Calcific valvular aortic disease</subject><subject>Cardiovascular risk</subject><subject>Coronary heart disease</subject><subject>Cut points</subject><subject>Humans</subject><subject>Hypolipidemic Agents - pharmacology</subject><subject>Lifestyle</subject><subject>Lipoprotein (a)</subject><subject>Lipoprotein(a) - blood</subject><subject>Lp(a)</subject><subject>Myocardial infarction</subject><subject>Practice Guidelines as Topic</subject><subject>Primary prevention</subject><subject>Scientific statement</subject><subject>Secondary prevention</subject><subject>Societies, Scientific</subject><subject>Stroke</subject><subject>Treatment</subject><issn>1933-2874</issn><issn>1876-4789</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtvEzEUhS0Eog_4AyyQl2Uxg19jjxGbqIKCFMGGri3XuVZumBkH2yniF_C3cZrCkpUf-u65OucQ8oqznjOu3-76nQ9TLxi3PVM94-wJOeej0Z0yo33a7lbKToxGnZGLUnaMDYNhw3NyJjlXRmh7Tn7fFqAp0jXu0z6nCrhc-TcUFxomXDD4ie6zDxUDvKMreodp9vk7ZPpzm9pkxRno1hca0gx9A0pAWCpGDLRUX2FuLxpzmmndAv3iK6alabZ1uKGrUlLAh78X5Fn0U4GXj-cluf344dv1p2799ebz9WrdBSVE7Zq5qAGihEFZboS1dhw0C1JYNUYFVnmjRWNlHEyQOkYOQUczeuWVBiEvydVJt5n9cYBS3YwlwDT5BdKhOCGkHIeWm2moOKEhp1IyRLfP2Nz_cpy5YwFu544FuGMBjinXCmhDrx_1D3czbP6N_E28Ae9PADSX9wjZPUQWYIMZQnWbhP_T_wOYaZc4</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Wilson, Don P.</creator><creator>Jacobson, Terry A.</creator><creator>Jones, Peter H.</creator><creator>Koschinsky, Marlys L.</creator><creator>McNeal, Catherine J.</creator><creator>Nordestgaard, Børge G.</creator><creator>Orringer, Carl E.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190501</creationdate><title>Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association</title><author>Wilson, Don P. ; Jacobson, Terry A. ; Jones, Peter H. ; Koschinsky, Marlys L. ; McNeal, Catherine J. ; Nordestgaard, Børge G. ; Orringer, Carl E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-876f6eef3e5491729998560c32948f4e94a762c423f57c36ff1ec6f78a4a46e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Atherosclerotic cardiovascular disease</topic><topic>Biomarker</topic><topic>Biomarkers - blood</topic><topic>Blood Chemical Analysis</topic><topic>Calcific valvular aortic disease</topic><topic>Cardiovascular risk</topic><topic>Coronary heart disease</topic><topic>Cut points</topic><topic>Humans</topic><topic>Hypolipidemic Agents - pharmacology</topic><topic>Lifestyle</topic><topic>Lipoprotein (a)</topic><topic>Lipoprotein(a) - blood</topic><topic>Lp(a)</topic><topic>Myocardial infarction</topic><topic>Practice Guidelines as Topic</topic><topic>Primary prevention</topic><topic>Scientific statement</topic><topic>Secondary prevention</topic><topic>Societies, Scientific</topic><topic>Stroke</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilson, Don P.</creatorcontrib><creatorcontrib>Jacobson, Terry A.</creatorcontrib><creatorcontrib>Jones, Peter H.</creatorcontrib><creatorcontrib>Koschinsky, Marlys L.</creatorcontrib><creatorcontrib>McNeal, Catherine J.</creatorcontrib><creatorcontrib>Nordestgaard, Børge G.</creatorcontrib><creatorcontrib>Orringer, Carl E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical lipidology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilson, Don P.</au><au>Jacobson, Terry A.</au><au>Jones, Peter H.</au><au>Koschinsky, Marlys L.</au><au>McNeal, Catherine J.</au><au>Nordestgaard, Børge G.</au><au>Orringer, Carl E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association</atitle><jtitle>Journal of clinical lipidology</jtitle><addtitle>J Clin Lipidol</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>13</volume><issue>3</issue><spage>374</spage><epage>392</epage><pages>374-392</pages><issn>1933-2874</issn><eissn>1876-4789</eissn><abstract>Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.
•Causal association between high lipoprotein(a) [Lp(a)] and atherosclerotic cardiovascular disease–related events and mortality.•Laboratory methods and population-based considerations for Lp(a) cut points.•When to measure Lp(a) in adults and youth.•Treatment implications in primary and secondary prevention.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31147269</pmid><doi>10.1016/j.jacl.2019.04.010</doi><tpages>19</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1933-2874 |
| ispartof | Journal of clinical lipidology, 2019-05, Vol.13 (3), p.374-392 |
| issn | 1933-2874 1876-4789 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2233859337 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Atherosclerotic cardiovascular disease Biomarker Biomarkers - blood Blood Chemical Analysis Calcific valvular aortic disease Cardiovascular risk Coronary heart disease Cut points Humans Hypolipidemic Agents - pharmacology Lifestyle Lipoprotein (a) Lipoprotein(a) - blood Lp(a) Myocardial infarction Practice Guidelines as Topic Primary prevention Scientific statement Secondary prevention Societies, Scientific Stroke Treatment |
| title | Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T01%3A06%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Lipoprotein(a)%20in%20clinical%20practice:%20A%20biomarker%20whose%20time%20has%20come.%20A%20scientific%20statement%20from%20the%20National%20Lipid%20Association&rft.jtitle=Journal%20of%20clinical%20lipidology&rft.au=Wilson,%20Don%20P.&rft.date=2019-05-01&rft.volume=13&rft.issue=3&rft.spage=374&rft.epage=392&rft.pages=374-392&rft.issn=1933-2874&rft.eissn=1876-4789&rft_id=info:doi/10.1016/j.jacl.2019.04.010&rft_dat=%3Cproquest_cross%3E2233859337%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2233859337&rft_id=info:pmid/31147269&rft_els_id=S1933287419300868&rfr_iscdi=true |